1 North Waukegan Road
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
1559 articles with AbbVie
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'.
For the families of children battling childhood cancer and other catastrophic diseases, days are often all but typical.
BioMed X and AbbVie Extend Research Collaboration in the USBioMed X establishes its first US-based institute in New Haven with a new immunology research project in collaboration with AbbVie.
BioMed X, an independent German biomedical research institute, announced today the extension of its ongoing research collaboration with AbbVie.
In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
Tuesday, AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology.
AbbVie and Immunome, Inc. announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine.
AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens.
Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, announced the second and third programs under the company's global partnership with AbbVie have advanced into lead generation.
In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.
AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.
AbbVie announced that the U.S. Food and Drug Administration has approved VRAYLAR® as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults.
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. Food and Drug Administration (FDA) for the treatment of children and adolescents 6 to 17 years of age with functional constipation (FC).
AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV).
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.
Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, announced the termination of its collaboration agreements with AbbVie, Inc. and Ipsen BioPharm Limited.
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
AbbVie announced data from multiple clinical trials evaluating epcoritamab, an investigational subcutaneous bispecific antibody, alone or in combination for the treatment of patients with relapsed/refractory follicular lymphoma, previously untreated FL, R/R diffuse large B-cell lymphoma, as well as Richter's syndrome at the 64th American Society of Hematology Annual Meeting.
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science
AbbVie announced new and updated data across clinical and real-world studies in chronic lymphocytic leukemia.
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
AbbVie announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.
In this episode of Discovery Files, we hear from veteran chemist Andy Souers, Ph.D., distinguished research fellow, AbbVie oncology discovery research, on how his team made a blood cancer discovery.